Literature DB >> 26147347

Anagliptin, a potent dipeptidyl peptidase IV inhibitor: its single-crystal structure and enzyme interactions.

Yukihisa S Watanabe1, Yoshika Yasuda1, Yuko Kojima2, Shino Okada3, Tomoko Motoyama3, Ryo Takahashi4, Mitsuru Oka1.   

Abstract

The single-crystal structure of anagliptin, N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide, was determined. Two independent molecules were held together by intermolecular hydrogen bonds, and the absolute configuration of the 2-cyanopyrrolidine ring delivered from l-prolinamide was confirmed to be S. The interactions of anagliptin with DPP-4 were clarified by the co-crystal structure solved at 2.85 Å resolution. Based on the structure determined by X-ray crystallography, the potency and selectivity of anagliptin were discussed, and an SAR study using anagliptin derivatives was performed.

Entities:  

Keywords:  Co-crystal structure; DPP-4 inhibitor; X-ray crystallography; transition-state interaction; type 2 diabetes

Mesh:

Substances:

Year:  2015        PMID: 26147347     DOI: 10.3109/14756366.2014.1002402

Source DB:  PubMed          Journal:  J Enzyme Inhib Med Chem        ISSN: 1475-6366            Impact factor:   5.051


  14 in total

1.  Predicting DPP-IV inhibitors with machine learning approaches.

Authors:  Jie Cai; Chanjuan Li; Zhihong Liu; Jiewen Du; Jiming Ye; Qiong Gu; Jun Xu
Journal:  J Comput Aided Mol Des       Date:  2017-02-02       Impact factor: 3.686

Review 2.  Does DPP-IV Inhibition Offer New Avenues for Therapeutic Intervention in Malignant Disease?

Authors:  Petr Busek; Jonathan S Duke-Cohan; Aleksi Sedo
Journal:  Cancers (Basel)       Date:  2022-04-21       Impact factor: 6.575

3.  SDR9C7 catalyzes critical dehydrogenation of acylceramides for skin barrier formation.

Authors:  Takuya Takeichi; Tetsuya Hirabayashi; Yuki Miyasaka; Akane Kawamoto; Yusuke Okuno; Shijima Taguchi; Kana Tanahashi; Chiaki Murase; Hiroyuki Takama; Kosei Tanaka; William E Boeglin; M Wade Calcutt; Daisuke Watanabe; Michihiro Kono; Yoshinao Muro; Junko Ishikawa; Tamio Ohno; Alan R Brash; Masashi Akiyama
Journal:  J Clin Invest       Date:  2020-02-03       Impact factor: 14.808

4.  Exploring the antidiabetic potential of compounds isolated from Anacardium occidentale using computational aproach: ligand-based virtual screening.

Authors:  Victor Okoliko Ukwenya; Sunday Aderemi Adelakun; Olusola Olalekan Elekofehinti
Journal:  In Silico Pharmacol       Date:  2021-04-03

5.  Comprehensive analysis of the Co-structures of dipeptidyl peptidase IV and its inhibitor.

Authors:  Hiroyuki Nojima; Kazuhiko Kanou; Genki Terashi; Mayuko Takeda-Shitaka; Gaku Inoue; Koichiro Atsuda; Chihiro Itoh; Chie Iguchi; Hajime Matsubara
Journal:  BMC Struct Biol       Date:  2016-08-05

6.  Dipeptidyl Peptidase-4 Inhibitor Anagliptin Prevents Intracranial Aneurysm Growth by Suppressing Macrophage Infiltration and Activation.

Authors:  Taichi Ikedo; Manabu Minami; Hiroharu Kataoka; Kosuke Hayashi; Manabu Nagata; Risako Fujikawa; Sei Higuchi; Mika Yasui; Tomohiro Aoki; Miyuki Fukuda; Masayuki Yokode; Susumu Miyamoto
Journal:  J Am Heart Assoc       Date:  2017-06-19       Impact factor: 5.501

7.  Crystal structures of a bacterial dipeptidyl peptidase IV reveal a novel substrate recognition mechanism distinct from that of mammalian orthologues.

Authors:  Saori Roppongi; Yoshiyuki Suzuki; Chika Tateoka; Mayu Fujimoto; Saori Morisawa; Ippei Iizuka; Akihiro Nakamura; Nobuyuki Honma; Yosuke Shida; Wataru Ogasawara; Nobutada Tanaka; Yasumitsu Sakamoto; Takamasa Nonaka
Journal:  Sci Rep       Date:  2018-02-09       Impact factor: 4.379

8.  Dipeptidyl Peptidase 4 Inhibitors Reduce Hepatocellular Carcinoma by Activating Lymphocyte Chemotaxis in Mice.

Authors:  Sohji Nishina; Akira Yamauchi; Takumi Kawaguchi; Kohei Kaku; Moritaka Goto; Kyo Sasaki; Yuichi Hara; Yasuyuki Tomiyama; Futoshi Kuribayashi; Takuji Torimura; Keisuke Hino
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2018-09-11

Review 9.  Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes.

Authors:  Enrique Z Fisman; Alexander Tenenbaum
Journal:  Cardiovasc Diabetol       Date:  2015-09-29       Impact factor: 9.951

10.  Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner.

Authors:  Munehiro Kitada; Shin-Ichi Tsuda; Kazunori Konishi; Ai Takeda-Watanabe; Mizue Fujii; Keizo Kanasaki; Makoto Nishizawa; Atsushi Nakagawa; Daisuke Koya
Journal:  BMJ Open Diabetes Res Care       Date:  2017-07-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.